Acurx Pharmaceuticals (ACXP)
(Delayed Data from NSDQ)
$2.01 USD
-0.03 (-1.47%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.99 -0.02 (-1.00%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ACXP 2.01 -0.03(-1.47%)
Will ACXP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ACXP based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ACXP
ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference
Acurx Pharmaceuticals’ Ibezapolstat: A Strong Buy Ahead of Phase 3 for CDI Treatment
Ibezapolstat’s Strategic Advancements and Market Potential Bolster Buy Rating for Acurx Pharmaceuticals
ACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q2 2024
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2024 Earnings Call Transcript